Pediatric Allergy Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables), By Allergen (Food, Inhaled, Drug), Test (In Vivo Test, In Vitro Test), By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Patient Handling Equipment Market Growth & Trends
The global patient handling equipment market is expected to reach USD 28.2 billion by 2030, according to a new report by Grand View Research, Inc., growing at CAGR of 6.6% from 2024 to 2030. The upsurge in the demand for products, such as slings, lifts, powered electric wheelchairs, due to the high risk of physical injuries in the manual lifting of heavy loads is a key growth driver of the patient handling equipment market. In addition, the growing prevalence of injuries, such as lower back pain, musculoskeletal disorders (MSDs), etc., is expected to boost growth in this sector. These injuries are avoidable by practicing safe patient handling guidelines and using equipment for the same.
Associated advantages and availability of improved products such as prime Transport Chairs (TC), temperature management systems, and patient transfer solutions, which offer safe, comfortable, and dignified transfer are the factors anticipated to provide lucrative growth to this sector in the near future.
Increasing incidences of Non-communicable Diseases (NCD), such as diabetes, asthma, cancer, stroke, etc., requiring patient handling equipment in homecare settings, hospitals, and intensive care units are further expected to boost market growth over the forecast period.
Patient Handling Equipment Market Report Highlights
Patient Handling Equipment Market Growth & Trends
The global patient handling equipment market is expected to reach USD 28.2 billion by 2030, according to a new report by Grand View Research, Inc., growing at CAGR of 6.6% from 2024 to 2030. The upsurge in the demand for products, such as slings, lifts, powered electric wheelchairs, due to the high risk of physical injuries in the manual lifting of heavy loads is a key growth driver of the patient handling equipment market. In addition, the growing prevalence of injuries, such as lower back pain, musculoskeletal disorders (MSDs), etc., is expected to boost growth in this sector. These injuries are avoidable by practicing safe patient handling guidelines and using equipment for the same.
Associated advantages and availability of improved products such as prime Transport Chairs (TC), temperature management systems, and patient transfer solutions, which offer safe, comfortable, and dignified transfer are the factors anticipated to provide lucrative growth to this sector in the near future.
Increasing incidences of Non-communicable Diseases (NCD), such as diabetes, asthma, cancer, stroke, etc., requiring patient handling equipment in homecare settings, hospitals, and intensive care units are further expected to boost market growth over the forecast period.
Patient Handling Equipment Market Report Highlights
- Wheelchairs have registered for the dominant market share, with 28.7% in 2023. The growing aged population and people with reduced mobility seek wheelchairs as a primary supportive mobility solution.
- Bariatric care has dominated the market in 2023 owing to the increasing senior population and obesity rates. Bariatric patients require specialized handling solutions due to their weight and mobility challenges.
- Hospitals secured the dominant market share with 46.4% in 2023 due to the geriatric population's increasing prevalence that necessitates specialized patient handling equipment.
- The North America patient handling equipment held the dominant market share, with 36.6% in 2023, owing to strict safety regulations implemented by healthcare institutions that ensure patient safety during handling and transport.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Allergen
1.2.3. Test
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Allergen outlook
2.2.3. Test outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. PEDIATRIC ALLERGY DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence of Pediatric Allergies
3.2.1.2. Growing Awareness of Allergies and Early Diagnosis
3.2.1.3. Advancements in Diagnostic Technologies
3.2.2. Market Restraint Analysis
3.2.2.1. High Costs of Diagnostic Tests
3.2.2.2. Lack of Awareness and Education
3.3. Pediatric Allergy Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. PEDIATRIC ALLERGY DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Pediatric Allergy Diagnostics Market: Product Movement Analysis
4.3. Pediatric Allergy Diagnostics Market by Product Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Instruments
4.5.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. Consumables
4.5.2.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Services
4.5.3.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. PEDIATRIC ALLERGY DIAGNOSTICS MARKET: ALLERGEN ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Pediatric Allergy Diagnostics Market: Allergen Movement Analysis
5.3. Pediatric Allergy Diagnostics Market by Allergen Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Food
5.5.1. Food Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.2. Dairy Products
5.5.2.1. Dairy Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.3. Poultry Product
5.5.3.1. Poultry Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.4. Tree Nuts
5.5.4.1. Tree Nuts Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.5. Peanuts
5.5.5.1. Peanuts Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.6. Shellfish
5.5.6.1. Shellfish Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.7. Wheat
5.5.7.1. Wheat Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.8. Soys
5.5.8.1. Soys Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.9. Other Food Allergens Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.9.1. Other Food Allergens Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Inhaled
5.6.1. Inhaled Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Drug
5.7.1. Drug Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Other Allergens
5.8.1. Other Allergens Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. PEDIATRIC ALLERGY DIAGNOSTICS MARKET: TEST ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Pediatric Allergy Diagnostics Market: Test Movement Analysis
6.3. Pediatric Allergy Diagnostics Market by Test Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. In vivo Test
6.5.1. In vivo Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Skin Prick Test
6.5.2.1. Skin Prick Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Intradermal Test
6.5.3.1. Intradermal Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. Patch Test
6.5.4.1. Patch Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. In vitro Test
6.6.1. In vitro Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. PEDIATRIC ALLERGY DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Key Company Profiles
8.3.1. R-Biopharm AG
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product benchmarking
8.3.1.4. Strategic initiatives
8.3.2. EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. AESKU.GROUP GmbH
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. bioMйrieux
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Thermo Fisher Scientific, Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Stallergenes Greer
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Minaris Medical America, Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Siemens Healthcare GmbH
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Omega Diagnostics Group PLC
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. HYCOR Biomedical
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Lincoln Diagnostics, Inc.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Allergen
1.2.3. Test
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Allergen outlook
2.2.3. Test outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. PEDIATRIC ALLERGY DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence of Pediatric Allergies
3.2.1.2. Growing Awareness of Allergies and Early Diagnosis
3.2.1.3. Advancements in Diagnostic Technologies
3.2.2. Market Restraint Analysis
3.2.2.1. High Costs of Diagnostic Tests
3.2.2.2. Lack of Awareness and Education
3.3. Pediatric Allergy Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. PEDIATRIC ALLERGY DIAGNOSTICS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Pediatric Allergy Diagnostics Market: Product Movement Analysis
4.3. Pediatric Allergy Diagnostics Market by Product Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Instruments
4.5.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. Consumables
4.5.2.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Services
4.5.3.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. PEDIATRIC ALLERGY DIAGNOSTICS MARKET: ALLERGEN ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Pediatric Allergy Diagnostics Market: Allergen Movement Analysis
5.3. Pediatric Allergy Diagnostics Market by Allergen Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Food
5.5.1. Food Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.2. Dairy Products
5.5.2.1. Dairy Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.3. Poultry Product
5.5.3.1. Poultry Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.4. Tree Nuts
5.5.4.1. Tree Nuts Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.5. Peanuts
5.5.5.1. Peanuts Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.6. Shellfish
5.5.6.1. Shellfish Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.7. Wheat
5.5.7.1. Wheat Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.8. Soys
5.5.8.1. Soys Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.9. Other Food Allergens Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.9.1. Other Food Allergens Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Inhaled
5.6.1. Inhaled Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Drug
5.7.1. Drug Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Other Allergens
5.8.1. Other Allergens Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. PEDIATRIC ALLERGY DIAGNOSTICS MARKET: TEST ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Pediatric Allergy Diagnostics Market: Test Movement Analysis
6.3. Pediatric Allergy Diagnostics Market by Test Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. In vivo Test
6.5.1. In vivo Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Skin Prick Test
6.5.2.1. Skin Prick Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Intradermal Test
6.5.3.1. Intradermal Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. Patch Test
6.5.4.1. Patch Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. In vitro Test
6.6.1. In vitro Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. PEDIATRIC ALLERGY DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Key Company Profiles
8.3.1. R-Biopharm AG
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product benchmarking
8.3.1.4. Strategic initiatives
8.3.2. EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. AESKU.GROUP GmbH
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. bioMйrieux
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Thermo Fisher Scientific, Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Stallergenes Greer
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Minaris Medical America, Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Siemens Healthcare GmbH
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Omega Diagnostics Group PLC
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. HYCOR Biomedical
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Lincoln Diagnostics, Inc.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
